




Remote Inspections & MHRA Innovation

Paula Walker, Deputy Inspectorate Group Manager, MHRA



 Medicines & Healthcare products Regulatory Agency

1

An “Unprecedented” Year

March 2020 Pandemic halted routine on-site inspections:

- Transformation of inspection model to remote
- High-risk or Covid-19 support inspections prioritised

<https://www.gov.uk/guidance/guidance-for-industry-on-mhras-expectations-for-return-to-uk-on-site-inspections>

Challenges

- Covid-19 guidance & managing clinical trials:

<https://www.gov.uk/government/collections/mhra-guidance-on-coronavirus-covid-19#clinical-trials>

- Vaccine & treatment inspection priorities
- EU Exit



2

2

Pre-Pandemic Remote Inspection Approaches

Majority of MHRA inspections on-site:

- GCP 'Day 1' office-based assessments
- 'Main' inspection in person
- Office based assessments for IAG cases


- Prior to pandemic, increasing levels of pre-inspection requests across GxPs. For GCP included:
 - Dossier
 - Procedures
 - Safety listings
 - Deviations and CAPA review etc.

3

3

GCP Inspections in a Pandemic

- Pragmatic approach implemented, reducing burden wherever possible
- Accommodates 'inspectees' working remotely as well as inspectors
- Inspection Reports still issued:
- Critical inspection findings raised across GxPs demonstrating effective remote approach
- >30 GCP inspections conducted to date



4

4

Logistics & Challenges

- Organisations notified as normal (unless triggered short-notice)
- Any pre-inspection documents requested & reviewed as normal
- Modified requests & dossiers ensuring needs of inspection scope are met
- Inspection scope often narrower than on-site, directed by risk
- Inspections take longer (often)
- Technical challenges!
- Inability to ask 'real-time' Qs
- Rapport building
- Visuals: Inability to easily assess state of premises/ equipment/ facilities

5

5

Industry Views

Diverse views on flexibility – some sites appreciated; others felt it extended on-site approach

Supports health & safety of the company staff

Allows for greater flexibility with work schedule of inspectees

Potentially remote inspections may warrant delaying an on-site inspection, or reduced scope of on-site – seen as positive

Motivation to continue standards of compliance even in extreme change

6

6

Hybrid Inspections & the Future



- MHRA operating 'Critical' and 'Covid-19 support' required inspections on-site only
 - From 29th March hybrid approaches continues, on-site if required
 - Overseas inspections & NHS on-site routine are paused
 - Inspection areas previously considered impossible remotely, have been challenged with successful outcomes...
 - Remote BE inspections taken forward into current 'routine' ways of working
- Focus remains on areas of risk**
- Remote investigator sites

7

7

What is ILAP? Innovative Licensing & Access Pathway

- Opportunity to think and practice differently after EU exit
- The ambition of ILAP is to deliver safe, early and financially sustainable patient access to innovative medicines
- Key aspect of ILAP is the partnership between the **MHRA, NICE and Scottish Medicines Consortium (SMC)**
- NHS-E and in Scotland are closely engaged, along with the Accelerated Access Collaborative and other UK health system partners including **HRA & NIHR**



8

8

Innovative Licensing and Access Pathway: ILAP

- A new medicine designation allows **Innovation Passport** to be awarded
- **Target Development Profile (TDP)** creates a unique UK roadmap, using the 'toolkit' & providing a platform for sustained multi-stakeholder collaboration
- Built-in flexibility, with multiple entry points along the pathway (non-clinical data → clinical trials)



- **4 products piloted pre-launch on 1st Jan 2021**
- **12 Innovation Passport applications in first 2 months**

<https://www.gov.uk/government/publications/innovative-licensing-and-access-pathway-ilap-for-medicines>

9

9

Enabling Regulator: The Toolkit

- Adaptive inspections
- Centre accreditation
- Novel CT methodology & design support
- Common medicine & device trial design
- Coordinated approvals process for co-developed medicines & IVDs
- CPRD assisted recruitment in clinical trials
- Rapid Clinical Trial Dossier pre-assessment service
- Certifications
- CPRD control groups
- Enhanced patient engagement
- Continuous benefit-risk assessments that integrate real world evidence
- New licensing procedures:
 - Rolling review
 - Accelerated timetables for marketing authorisation, flexibilities
- International options
 - FDA Orbis
 - ACCESS

10

10

© Crown Copyright 2021

About Copyright

All material created by the MHRA, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty's Stationery Office (HMSO).

The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA.

Further information, including an application form for requests to reproduce our material can be found at <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

Material from Other Organisations

The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned.